Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
250000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
発行・処分する株式数
Number of shares delivered during the month: 250,000 shares (250,000 new shares, 0 treasury shares transferred)
Intended allottee
EVO FUND (the allottee of the previously issued Stock Acquisition Rights)
Terms of the stock acquisition rights
Exercise price
The exercise price during the month under review ranged from ¥109 to ¥135 per share. Details of the adjustment clause and the lower limit are Not disclosed
Number of Stock Acquisition Rights
Total issued: 82,700 rights; exercised during the month under review: 2,500 rights; unexercised at the end of the month preceding the month under review: 41,700 rights; unexercised at the end of the month under review: 39,200 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions pursuant to Article 434 of the Listing Regulations. The number of shares delivered across all series was 250,000, the number of listed shares as of the payment date for the issuance was 9,828,500, and the exercise ratio subject to the exercise restrictions was 2.5%.
Most recent equity financing
The 10th Series of Stock Acquisition Rights issued on 13 February 2026 and allotted to EVO FUND (total issued: 82,700 rights)
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 250,000 shares (250,000 new shares, 0 treasury shares transferred) |
| Intended allottee | EVO FUND (the allottee of the previously issued Stock Acquisition Rights) |
| Total number of issued shares | 16,528,500 shares (as of the end of the month preceding the month under review, including 20 treasury shares) → Not disclosed |
| Exercise price | The exercise price during the month under review ranged from ¥109 to ¥135 per share. Details of the adjustment clause and the lower limit are Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 82,700 rights; exercised during the month under review: 2,500 rights; unexercised at the end of the month preceding the month under review: 41,700 rights; unexercised at the end of the month under review: 39,200 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions pursuant to Article 434 of the Listing Regulations. The number of shares delivered across all series was 250,000, the number of listed shares as of the payment date for the issuance was 9,828,500, and the exercise ratio subject to the exercise restrictions was 2.5%. |
| Most recent equity financing | The 10th Series of Stock Acquisition Rights issued on 13 February 2026 and allotted to EVO FUND (total issued: 82,700 rights) |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status and compliance with the exercise restrictions.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.